Syndax(美国)
Syndax
Syndaxwww.syndax.comSyndax制药专注于运用表观遗传学相关的方法,克服在实体瘤治疗中发生的耐药性问题。公司拥有Entinostat在全球的专利权。Entinostat是一种口服的、高选择性的组蛋白去乙酰化酶(HDAC)抑制剂,用于晚期乳腺癌和肺癌的临床治疗。同样在一组非小细胞肺癌患者的治疗中(ENCORE401),Entinostat与EGFR-TKI厄洛替尼配合使用也取得了
积极有效的结果。美国国家癌症研究所(NCI)和Syndax制药就Entinostat的发展达成了合作研究和开发协议,旨在改善晚期癌症和难治性癌症的存活率。Syndaxisfocusedonemployingepigeneticstrategiestoovercometheproblemofresistanceinoncologycareinsolidtumors.Thecompanyholdsworldwiderightstoentinostat,anoral,highlyselectivehistonedeacetylase(HDAC)inhibitorinlate-stageclinicaldevelopmentforthetreatmentofadvancedbreastcancerandlungcancer.Arandomized,placebo-controlledPhase2studyofentinostatincombinationwitharomataseinhibitorsinbreastcancer(ENCORE301)demonstratedanimprovementinbothprogression-freesurvivalandoverallsurvival,providingthebasisfortheevaluationofentinostatinpivotalPhase3testinginmetastaticbreastcancer.Entinostatalsodemonstratedpromis